Cyclosporine attenuates the adenylyl cyclase superactivation induced by chronic cannabinoid treatment

European Journal of Pharmacology

Volumn 557, Issue 1, 2007, Pages 20-22

  Banafshe, Hamid R ^a   Ghazi Khansari, Mahmoud ^a   Ejtemaei Mehr, Shahram ^a   Dehpour, Ahmad R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adenylyl cyclase superactivation; Cannabinoid; Cyclosporine

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADENYLATE CYCLASE; CYCLOSPORIN A;

ARTICLE; ASTROCYTOMA CELL; CELL MATURATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LONG TERM EXPOSURE; PRIORITY JOURNAL;

ADENYLATE CYCLASE; CANNABINOIDS; CELL LINE, TUMOR; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID;

EID: 33846336539     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.11.019     Document Type: Article

References (21)

1. Banafshe H.R., Ghazi-Khansari M., and Dehpour A.R. The effect of cyclosporine on the development and expression of cannabinoid tolerance in mice. Pharmacol. Biochem. Behav. 82 (2005) 658-663
2. Dill J.A., and Howlett A.C. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J. Pharmacol. Exp. Ther. 244 (1988) 1157-1163
3. Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., and Feldman R.D. Raf kinase activation of adenylyl cyclases: isoform-selective regulation. Mol. Pharmacol. 66 (2004) 921-928
4. Ejtemaei Mehr S., Samini M., Namiranian K., Homayoun H., Gaskari S.A., and Dehpour A.R. Inhibition by immunophilin ligands of morphine-induced tolerance and dependence in guinea pig ileum. Eur. J. Pharmcol. 467 (2003) 205-210
5. Gary-Gouy H., Sainz-Perez A., Bismuth G., Ghadiri A., Perrino B.A., and Dalloul A. Cyclosporin-A inhibits ERK phosphorylation in B cells by modulating the binding of Raf protein to Bcl2. Biochem. Biophys. Res. Commun. 344 (2006) 134-139
6. Groblewski G.E., Wagner A.C., and Williams J.A. Cyclosporin A inhibits Ca2+/calmodulin-dependent protein phosphatase and secretion in pancreatic acinar cells. J. Biol. Chem. 269 (1994) 15111-15117
7. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., and Speicher D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226 (1984) 544-557
8. Homayoun H., Khavandgar S., Namiranian K., and Dehpour A.R. The effect of cyclosporin A on morphine tolerance and dependence: involvement of nitric oxide pathway. Eur. J. Pharmacol. 452 (2002) 67-75
9. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. pharmacol. Toxicol. 35 (1995) 607-634
10. Mackie K., Westenbroek LaiY., and Mitchell R. Cannabinoid activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in atT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15 (1995) 6552-6561
11. Matsuda L.A., Lolait S., Brownstein M.J., Young A.C., and Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
12. Munro S., Thomas K.L., and Abu-shaar M. Molecular characterization of peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
13. Rhee M.H., Nevo I., Avidor-Reiss T., Levy R., and Vogel Z. Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB1 cannabinoid receptor. Mol. Pharmacol. 57 (2000) 746-752
14. Rubino T., Vigano' D., Massi P., Spinello M., Zagato E., Giagnoni G., and Parolaro D. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39 (2000) 1331-1336
15. Shapira M., Gafni M., and Sarne Y. Long term interaction between opioid and cannabinoid agonists at the cellular level: cross-desensitization and down regulation. Brain Res. 960 (2003) 190-200
16. Steiner J.P., Dawson T.M., Fotuhi M., Glatt C.E., Snowmam A.M., Cohen N., and Snyder S.H. High brain densities of immunophilin FKBP colocalized with calcineurin. Nature 358 (1992) 584-587
17. Synder S.H., Sabatini T.M., Lai M.M., Steiner J.P., Hamilton G.S., and Suzdac P.D. Neural action of immunophilin ligands. Trends Pharmacol. Sci. 19 (1998) 21-26
18. Tan C.M., Kelvin D.J., Litchfield D.W., Ferguson S.S.G., and Feldman R.D. Tyrosine kinase-mediated serine phosphorylation of adenylyl cyclase. Biochemistry 40 (2001) 1702-1709
19. Varga E.V., Rubenzik M.K., Stropova D., Sugiyama M., Grife V., Hruby V.J., Rice K.C., Roeske W.R., and Yamamura H.I. Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment. J. Pharmacol. Exp. Ther. 306 (2003) 109-115
20. Walker R.J., Lazzaro V.A., Duggin G.G., Horvath J.S., and Tiller D.J. Cyclosporin A inhibits protein kinase C activity: a contributing mechanism in the development of nephrotoxicity. Biochem. Biophys. Res. Commun. 160 (1989) 409-415
21. Yue X., Varga E.V., Stropova D., Vanderah T.W., Yamamura H.I., and Roeske W.R. Chronic morphine-mediated adenylyl cyclase superactivation is attenuated by the Raf-1 inhibitor, GW5074. Eur. J. Pharmacol. 540 (2006) 57-59